Bevacizumab combined with re-irradiation in recurrent glioblastoma

BACKGROUND: Glioblastoma is characterized by rich vasculature and abnormal vascular structure and function. Currently, there is no standard treatment for recurrent glioblastoma (rGBM). Bevacizumab (BEV) has established role of inhibiting neovascularization, alleviating hypoxia in the tumor area and...

Descripción completa

Detalles Bibliográficos
Autores principales: She, Lei, Su, Lin, Liu, Chao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9423039/
https://www.ncbi.nlm.nih.gov/pubmed/36046037
http://dx.doi.org/10.3389/fonc.2022.961014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9423039/
https://www.ncbi.nlm.nih.gov/pubmed/36046037
http://dx.doi.org/10.3389/fonc.2022.961014

Ejemplares similares